Rezolute

About Rezolute

Rezolute Inc is a late-stage biopharmaceutical company focused on developing transformative therapies for rare and metabolic diseases. Its lead product candidate, ersodetug, is in Phase 3 clinical trials for congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive insulin secretion and hypoglycemia. Rezolute is also developing RZ402, an oral plasma kallikrein inhibitor in Phase 2 trials for the chronic treatment of diabetic macular edema. The company is dedicated to addressing serious unmet medical needs and improving outcomes for patients with rare diseases.